GoodRx Appoints Dorothy Gemmell as Chief Commercial Officer

Gemmell to co-lead Pharma Manufacturer Solutions business, oversee GoodRx Health and Provider Mode

GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company’s Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies.

Gemmell brings with her a strong track record leading high-growth teams and building trusted, market-leading healthcare companies that provide solutions to pharmaceutical companies, provider organizations and health plans. She has served as an advisor to GoodRx for two years, during which she focused on growth, go-to-market strategy and the development of GoodRx's healthcare provider offering, strengthening GoodRx’s overall B2B value proposition to the pharmaceutical and medical device industry. With more than 30 years of industry experience, Gemmell will now work to expand the roster of brands that leverage GoodRx’s leading awareness, access and adherence platform that is used by millions of consumers and has helped over 900,000 prescribers, and scale GoodRx’s solutions for helping patients start and stay on their medications.

“Dorothy is a successful, well-rounded healthcare executive with a terrific track record of building teams, delivering results for customers and creating revenue growth,” said Scott Wagner, Interim CEO of GoodRx. “Dorothy knows GoodRx well and has a great combination of strategic insight and execution discipline. Everyone at GoodRx is thrilled that Dorothy is joining our team.”

In addition to working on Pharma Manufacturer Solutions, Gemmell will oversee the strategy and operations of GoodRx Health, the trusted and award-winning content arm of GoodRx, where she will continue building on its mission of creating impactful and unbiased health content for consumers. Gemmell will also manage the company’s offerings for healthcare providers (HCPs), including the recently launched Provider Mode, which is a platform built to help HCPs find affordable solutions for the medications they prescribe.

“I’m excited to join the GoodRx leadership team as we expand our opportunities for healthcare brands across our consumer and provider offerings,” said Gemmell. “Grounded in our mission to make medications more affordable and accessible, I will be looking for new ways to help manufacturers surface their savings, adherence and patient support programs to providers and consumers in effective ways at the most meaningful points in the patient journey to improve patient outcomes.”

Gemmell previously served as Head of Commercial for digital pharmacy Capsule, Chief Commercial Officer for telebehavioral health company AbleTo, and held senior leadership roles at Havas Health, Practice Fusion and WebMD/Medscape. During her thirteen years at WebMD, she managed the sales teams and helped scale the company while building consumer and healthcare provider trust.

About GoodRx

GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $55 billion and are one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations, growth and financial results, our potential for growth, our relationship with industry participants and partners and other third parties, demand for our offerings, benefits to consumers from our offerings, and the benefits of new hires and anticipated contributions from Gemmell and Crittenden in their new roles. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and in our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230710669577/en/